Literature DB >> 19496186

Renin-angiotensin system in the pathogenesis of liver fibrosis.

Regina Maria Pereira1, Robson Augusto Souza dos Santos, Filipi Leles da Costa Dias, Mauro Martins Teixeira, Ana Cristina Simões e Silva.   

Abstract

Hepatic fibrosis is considered a common response to many chronic hepatic injuries. It is a multifunctional process that involves several cell types, cytokines, chemokines and growth factors leading to a disruption of homeostatic mechanisms that maintain the liver ecosystem. In spite of many studies regarding the development of fibrosis, the understanding of the pathogenesis remains obscure. The hepatic tissue remodeling process is highly complex, resulting from the balance between collagen degradation and synthesis. Among the many mediators that take part in this process, the components of the Renin angiotensin system (RAS) have progressively assumed an important role. Angiotensin (Ang) II acts as a profibrotic mediator and Ang-(1-7), the newly recognized RAS component, appears to exert a counter-regulatory role in liver tissue. We briefly review the liver fibrosis process and current aspects of the RAS. This review also aims to discuss some experimental evidence regarding the participation of RAS mediators in the pathogenesis of liver fibrosis, focusing on the putative role of the ACE2-Ang-(1-7)-Mas receptor axis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19496186      PMCID: PMC2691487          DOI: 10.3748/wjg.15.2579

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  79 in total

1.  Angiotensin II induces contraction and proliferation of human hepatic stellate cells.

Authors:  R Bataller; P Ginès; J M Nicolás; M N Görbig; E Garcia-Ramallo; X Gasull; J Bosch; V Arroyo; J Rodés
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

2.  Opposing actions of angiotensins on angiogenesis.

Authors:  R D Machado; R A Santos; S P Andrade
Journal:  Life Sci       Date:  2000       Impact factor: 5.037

3.  Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis.

Authors:  J R Jonsson; A D Clouston; Y Ando; L I Kelemen; M J Horn; M D Adamson; D M Purdie; E E Powell
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

Review 4.  Angiotensin II and renal fibrosis.

Authors:  S A Mezzano; M Ruiz-Ortega; J Egido
Journal:  Hypertension       Date:  2001-09       Impact factor: 10.190

5.  A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase.

Authors:  S R Tipnis; N M Hooper; R Hyde; E Karran; G Christie; A J Turner
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

Review 6.  The hyperdynamic circulation in cirrhosis: an overview.

Authors:  L Blendis; F Wong
Journal:  Pharmacol Ther       Date:  2001-03       Impact factor: 12.310

7.  Effects of single dose of 50mg captopril in patients with liver cirrhosis and ascites.

Authors:  J K Lee; J F Hsieh; S C Tsai; Y J Ho; C H Kao
Journal:  Hepatogastroenterology       Date:  2000 May-Jun

8.  A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.

Authors:  M Donoghue; F Hsieh; E Baronas; K Godbout; M Gosselin; N Stagliano; M Donovan; B Woolf; K Robison; R Jeyaseelan; R E Breitbart; S Acton
Journal:  Circ Res       Date:  2000-09-01       Impact factor: 17.367

Review 9.  Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases.

Authors:  S Kim; H Iwao
Journal:  Pharmacol Rev       Date:  2000-03       Impact factor: 25.468

10.  Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis.

Authors:  N Girgrah; P Liu; J Collier; L Blendis; F Wong
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

View more
  34 in total

Review 1.  Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists.

Authors:  Ahmed A Magan; Atif A Khalil; Mohamed H Ahmed
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

Review 2.  Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review.

Authors:  Gaeun Kim; Juyoung Kim; Yoo Li Lim; Moon Young Kim; Soon Koo Baik
Journal:  Hepatol Int       Date:  2016-02-22       Impact factor: 6.047

3.  Risk Assessment of Hepatocellular Carcinoma in General Population by Liver Stiffness in Combination with Controlled Attenuation Parameter using Transient Elastography: A Cross Sectional Study.

Authors:  Takaaki Sugihara; Masahiko Koda; Tomomitsu Matono; Kinya Okamoto; Yoshikazu Murawaki; Hajime Isomoto; Shiho Tokunaga
Journal:  Yonago Acta Med       Date:  2017-06-26       Impact factor: 1.641

Review 4.  The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis.

Authors:  Takako Nagai; Kyoko Nitta; Megumi Kanasaki; Daisuke Koya; Keizo Kanasaki
Journal:  Clin Exp Nephrol       Date:  2014-07-01       Impact factor: 2.801

5.  Targeting the renin-angiotensin-aldosterone system in fibrosis.

Authors:  Mohammad AlQudah; Taben M Hale; Michael P Czubryt
Journal:  Matrix Biol       Date:  2020-05-16       Impact factor: 11.583

6.  Dynamic Variation of RAS on Silicotic Fibrosis Pathogenesis in Rats.

Authors:  Bo-Nan Zhang; Xin Zhang; Hong Xu; Xue-Min Gao; Gui-Zhen Zhang; Hui Zhang; Fang Yang
Journal:  Curr Med Sci       Date:  2019-07-25

7.  High-salt diets during pregnancy affected fetal and offspring renal renin-angiotensin system.

Authors:  Caiping Mao; Rong Liu; Le Bo; Ningjing Chen; Shigang Li; Shuixiu Xia; Jie Chen; Dawei Li; Lubo Zhang; Zhice Xu
Journal:  J Endocrinol       Date:  2013-06-01       Impact factor: 4.286

8.  Angiotensin II mediates cell survival through upregulation and activation of the serum and glucocorticoid inducible kinase 1.

Authors:  Rebekah Baskin; Peter P Sayeski
Journal:  Cell Signal       Date:  2011-09-22       Impact factor: 4.315

Review 9.  Animal models of scleroderma: current state and recent development.

Authors:  Yoshihide Asano; Shinichi Sato
Journal:  Curr Rheumatol Rep       Date:  2013-12       Impact factor: 4.592

10.  Fugan Wan alleviates hepatic fibrosis by inhibiting ACE/Ang II/AT-1R signaling pathway and enhancing ACE2/Ang 1-7/Mas signaling pathway in hepatic fibrosis rat models.

Authors:  Shu Li; Wei Zhao; Yanyan Tao; Chenghai Liu
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.